[go: up one dir, main page]

WO2006116688A3 - Mif agonists and antagonists and therapeutic uses thereof - Google Patents

Mif agonists and antagonists and therapeutic uses thereof Download PDF

Info

Publication number
WO2006116688A3
WO2006116688A3 PCT/US2006/016254 US2006016254W WO2006116688A3 WO 2006116688 A3 WO2006116688 A3 WO 2006116688A3 US 2006016254 W US2006016254 W US 2006016254W WO 2006116688 A3 WO2006116688 A3 WO 2006116688A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
disease associated
mif expression
antagonists
low mif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/016254
Other languages
French (fr)
Other versions
WO2006116688A2 (en
Inventor
Richard Bucala
Lin Leng
Sarah Doernberg
Michael Bukrinsky
Seamas Donnelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to US11/919,307 priority Critical patent/US20100143379A1/en
Publication of WO2006116688A2 publication Critical patent/WO2006116688A2/en
Publication of WO2006116688A3 publication Critical patent/WO2006116688A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods and compositions for selecting a subject for treatment with an agonist or antagonist of macrophage migration inhibitory factor (MIF), identifying a subject at risk for developing a disease associated with high or low MIF expression, predicting the severity of a disease associated with high or low MIF expression in a subject, and for predicting whether a subject is susceptible to a disease associated with high or low MIF expression. The invention also provides novel methods of diagnosing a patient for a disease associated with high or low MIF expression. Also provided are methods for treating a subject having a disease or disorder associated with high or low MIF expression.
PCT/US2006/016254 2005-04-26 2006-04-26 Mif agonists and antagonists and therapeutic uses thereof Ceased WO2006116688A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/919,307 US20100143379A1 (en) 2005-04-26 2006-04-26 Mif agonists and antagonist and therapeutic uses thereof

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US67530305P 2005-04-26 2005-04-26
US60/675303 2005-04-26
US68553305P 2005-05-27 2005-05-27
US60/685533 2005-05-27
US68748105P 2005-06-02 2005-06-02
US60/687481 2005-06-02
US68886505P 2005-06-08 2005-06-08
US60/688865 2005-06-08
US69883305P 2005-07-12 2005-07-12
US60/698833 2005-07-12
US72504905P 2005-10-07 2005-10-07
US60/725049 2005-10-07
US73279705P 2005-11-02 2005-11-02
US60/732797 2005-11-02

Publications (2)

Publication Number Publication Date
WO2006116688A2 WO2006116688A2 (en) 2006-11-02
WO2006116688A3 true WO2006116688A3 (en) 2007-07-26

Family

ID=37215552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/016254 Ceased WO2006116688A2 (en) 2005-04-26 2006-04-26 Mif agonists and antagonists and therapeutic uses thereof

Country Status (1)

Country Link
WO (1) WO2006116688A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072963B1 (en) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
US8367350B2 (en) 2009-04-29 2013-02-05 Morehouse School Of Medicine Compositions and methods for diagnosis, prognosis and management of malaria
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
CA3201648A1 (en) * 2020-12-11 2022-06-16 Robin VAN BRUGGEN Treatment and prevention of anaemia of inflammation
CN115252636A (en) * 2022-06-15 2022-11-01 南方医科大学顺德医院(佛山市顺德区第一人民医院) Oligodeoxynucleotide and application thereof in preparation of antitumor drugs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083813A1 (en) * 2000-05-02 2001-11-08 Centre National De La Recherche Scientifique Identification of genetic markers
WO2002007720A1 (en) * 2000-07-26 2002-01-31 The Picower Institute For Medical Research Compounds having mif antagonist activity
US20030099653A1 (en) * 1993-05-17 2003-05-29 Bucala Richard J. Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
WO2003060468A2 (en) * 2001-12-21 2003-07-24 Cytokine Pharmasciences, Inc. Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease
WO2005020919A2 (en) * 2003-08-29 2005-03-10 Cytokine Pharmasciences, Inc. Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099653A1 (en) * 1993-05-17 2003-05-29 Bucala Richard J. Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
WO2001083813A1 (en) * 2000-05-02 2001-11-08 Centre National De La Recherche Scientifique Identification of genetic markers
WO2002007720A1 (en) * 2000-07-26 2002-01-31 The Picower Institute For Medical Research Compounds having mif antagonist activity
WO2003060468A2 (en) * 2001-12-21 2003-07-24 Cytokine Pharmasciences, Inc. Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease
WO2005020919A2 (en) * 2003-08-29 2005-03-10 Cytokine Pharmasciences, Inc. Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAUGH & DONNELLY: "Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation.", THE JOURNAL OF ENDOCRINOLOGY. OCT 2003, vol. 179, no. 1, October 2003 (2003-10-01), pages 15 - 23, XP002408028, ISSN: 0022-0795 *
BAUGH J A ET AL: "A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis.", GENES AND IMMUNITY. MAY 2002, vol. 3, no. 3, May 2002 (2002-05-01), pages 170 - 176, XP008039746, ISSN: 1466-4879 *
DE BENEDETTI FABRIZIO ET AL: "FUNCTIONAL AND PROGNOSTIC RELEVANCE OF THE -173 POLYMORPHISM OF THE MACROPHAGE MIGRATION INHIBITORY FACTOR GENE IN SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 48, no. 5, May 2003 (2003-05-01), pages 1398 - 1407, XP008071511, ISSN: 0004-3591 *
DONN RACHELLE P ET AL: "Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY. SEP 2004, vol. 123, no. 3, September 2004 (2004-09-01), pages 484 - 487, XP002408026, ISSN: 0022-202X *
MORAND ERIC F ET AL: "Macrophage Migration Inhibitory Factor", ARTHRITIS AND RHEUMATISM. FEB 2003, vol. 48, no. 2, February 2003 (2003-02-01), pages 291 - 299, XP002408029, ISSN: 0004-3591 *
RENNER ET AL: "Macrophage Migration Inhibitory Factor: Gene polymorphisms and susceptibility to inflammatory disease.", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 41, 15 November 2005 (2005-11-15), pages S513 - S519, XP008071560, ISSN: 1058-4838 *
SHI ET AL: "Technologies for detecting genetic polymorphisms in pharmacogenomics", MOLECULAR DIAGNOSIS, NAPERVILLE, IL, US, vol. 4, no. 4, December 1999 (1999-12-01), pages 343 - 351, XP005533504, ISSN: 1084-8592 *
SHI M W: "TECHNOLOGIES FOR INDIVIDUAL GENOTYPING: DETECTION OF GENETIC POLYMORHPISMS IN DRUG TARGETS AND DISEASE GENES", AMERICAN JOURNAL OF PHARMACOGENOMICS, XX, XX, vol. 2, no. 3, 2002, pages 197 - 205, XP009065150, ISSN: 1175-2203 *
ZHONG XIAO-BO ET AL: "Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies.", NUCLEIC ACIDS RESEARCH. 2005, vol. 33, no. 13, 2005, pages e121, XP002408027, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
WO2006116688A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2009101059A3 (en) Methods of using cadherin 11 (cdh11) antagonists
WO2010036960A8 (en) Methods for treating, diagnosing, and monitoring lupus
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2009055001A3 (en) Methods of treating aging and methods of screening candidate agents therefor
WO2005023291A3 (en) Use of glp1-agonists in the treatment of patients with type i diabetes
WO2006116688A3 (en) Mif agonists and antagonists and therapeutic uses thereof
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2007044622A8 (en) Use of mif and mif pathway agonists
MXPA05008805A (en) Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases.
WO2003070902A3 (en) Receptors and membrane-associated proteins
EP2539709A4 (en) ALTERNATIVES SPECIFIC TO ALZHEIMER'S DISEASE PROTEIN KINASE C EPSILON LEVELS (PKC-EPSILON)
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
ATE402739T1 (en) TREATMENT OF INFLAMMATION
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
WO2004048550A3 (en) Immune response associated proteins
WO2005000099A3 (en) BLOOD FACTOR DOMAINS (BFDs)
WO2004048529A3 (en) Cell adhesion and extracellular matrix proteins
BRPI0515727A (en) biomarker for heart failure
Theodoropoulos et al. Prospective evaluation of health-related quality of life in a homogeneous Mediterranean group of colorectal cancer patients

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06751775

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11919307

Country of ref document: US